ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine

Its studies are mostly in Influenza, Human, led by GlaxoSmithKline.

Furthest: phase 1, since Mar 6, 20261 company-led study, 1 open or runningNext primary completion: Dec 3, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline11 open or runningphase 1since Mar 6, 2026Mar 6, 2026Dec 3, 2026phase 1 · NCT07464314

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 6, 2026First study: phase 1 study in Influenza, HumanFirst studyNCT07464314 · 225 planned · United States

Ahead

  1. Dec 3, 2026Primary completion: phase 1 study in Influenza, HumanNCT07464314

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine”name, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07464314Influenza, Human · United States1RecruitingDec 3, 2026225

How it is read

Names in the registry

  • “Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.